In a new study scientists have revealed the anti-proliferative and apoptotic effect of arctigenin on renal cancer cells and its apoptotic effect associated with deactivation of PI3K/Akt pathway in renal cancer cells1.
Renal Cancer is the 2nd among the urinary tract system disorders around the world. It overall ranks in 6th reason for death causing a million deaths per year2. Tailing along the surgical removal of localized renal cancer, 30-40% patients tend to develop metastatic renal carcinoma3.
The treatment for renal cancer is still the same like; chemotherapy, immunotherapy and targeted therapy. But the lack of response towards these therapies demands for new and effective approaches to cure RCC4. Natural products are among these novel therapeutic compounds which are being widely studied against various cancer cell lines5.
Lately a polyphenol extracted from plants, arctigenin has been investigated for its biological effects such as anti-inflammatory, anti-oxidant, anti-viral and anti-cancer properties6. The mechanism identified for anti-proliferative effect of arctigenin on various cancers is apoptosis7.
Cell performs apoptosis by different pathways including phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway8. PI3K is a dimer enzyme which contributes to the cell proliferation and survival after cytokine activation. It is followed by Akt mediated biological responses which is a downstream effecter molecule of PI3K. Further, the downstream substrates of Akt contribute to the stimulation of cell survival signals either in cytoplasm or nucleus9.
So the researchers studied this pathway for Renal Cancer Cells. For this purpose dose dependent cell viability and cytotoxicity assay of arctigenin on 786-O RCC line was performed. After that, arctigenin-induced cell cycle seizure and apoptotic cell death was evaluated using flow cytometry. The effect of arctigenin in regulating pro-apoptotic cascade and PI3k/Akt pathway was also analyzed using standard kits.
It was found that significant anti-proliferative effect of arctigenin on 786-O RCC line in dose dependent form. The connection between signaling molecules in inducing apoptosis was confirmed and further the PI3k/Akt signaling pathway was down regulated, in a dosed dependent manner.
So this study demonstrated that the arctigenin exerts cytotoxic activity on renal cancer cells and perform apoptotic activity by down-regulating PI3k/Akt signaling pathway.
Written by: Rabeeia
Your email address will not be published. Required fields are marked *
17 November, 2019